NZ773177A - Neuroactive steroid formulations and methods of treating cns disorders - Google Patents
Neuroactive steroid formulations and methods of treating cns disordersInfo
- Publication number
- NZ773177A NZ773177A NZ773177A NZ77317713A NZ773177A NZ 773177 A NZ773177 A NZ 773177A NZ 773177 A NZ773177 A NZ 773177A NZ 77317713 A NZ77317713 A NZ 77317713A NZ 773177 A NZ773177 A NZ 773177A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- cns disorders
- neuroactive steroid
- treating cns
- steroid formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261589740P | 2012-01-23 | 2012-01-23 | |
| NZ755699A NZ755699B2 (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating CNS disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ773177A true NZ773177A (en) | 2022-09-30 |
Family
ID=48874058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ773177A NZ773177A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
| NZ627781A NZ627781A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ627781A NZ627781A (en) | 2012-01-23 | 2013-01-23 | Neuroactive steroid formulations and methods of treating cns disorders |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20150018327A1 (enExample) |
| EP (3) | EP3650027A1 (enExample) |
| JP (5) | JP2015513316A (enExample) |
| CN (2) | CN112472814A (enExample) |
| AU (3) | AU2013212287B2 (enExample) |
| BR (1) | BR112014018110B1 (enExample) |
| CA (1) | CA2862076C (enExample) |
| CY (1) | CY1122527T1 (enExample) |
| DK (1) | DK2806877T3 (enExample) |
| ES (1) | ES2758446T3 (enExample) |
| HR (1) | HRP20192348T1 (enExample) |
| HU (1) | HUE046800T2 (enExample) |
| IL (4) | IL286348B2 (enExample) |
| LT (1) | LT2806877T (enExample) |
| MX (3) | MX2014008895A (enExample) |
| NZ (2) | NZ773177A (enExample) |
| PL (1) | PL2806877T3 (enExample) |
| PT (1) | PT2806877T (enExample) |
| RS (1) | RS59734B1 (enExample) |
| RU (2) | RU2019104004A (enExample) |
| SG (2) | SG11201503882SA (enExample) |
| SI (1) | SI2806877T1 (enExample) |
| SM (1) | SMT202000008T1 (enExample) |
| WO (1) | WO2013112605A2 (enExample) |
| ZA (1) | ZA201405401B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008006888A (es) | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Formulas y metodos para la manufactura y uso de la ganaxolona. |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| WO2014071449A1 (en) * | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016061527A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| WO2017031239A1 (en) | 2015-08-18 | 2017-02-23 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
| US10780099B2 (en) * | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10858338B2 (en) | 2016-03-15 | 2020-12-08 | The Regents Of The University Of California | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) |
| ES2992037T3 (es) | 2016-07-11 | 2024-12-05 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización |
| JP7049313B2 (ja) | 2016-07-11 | 2022-04-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
| JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | てんかん性障害の処置のための方法および組成物 |
| US20180050107A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108148106A (zh) | 2016-12-05 | 2018-06-12 | 江苏恩华络康药物研发有限公司 | 一类水溶性别孕烯醇酮衍生物及其用途 |
| US20210228596A1 (en) | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| AU2018364659A1 (en) * | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| WO2020011789A1 (en) | 2018-07-09 | 2020-01-16 | Asarina Pharma Ab | Injectable suspensions |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| US20220202832A1 (en) * | 2019-04-05 | 2022-06-30 | The Regents Of The University Of California | Allopregnanolone compositions and uses thereof |
| EP3965772A4 (en) | 2019-05-10 | 2023-05-10 | Brii Biosciences, Inc. | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CA3158280A1 (en) | 2019-12-06 | 2021-06-10 | Alex Aimetti | Ganaxolone for use in treating tuberous sclerosis complex |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| CN116917134A (zh) * | 2020-12-02 | 2023-10-20 | 约翰霍普金斯大学 | 用于神经调节剂的包封和持续释放的聚合物纳米颗粒组合物 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| EP4392036A1 (en) * | 2021-08-26 | 2024-07-03 | Brandeis University | Selective isonitrile inhibitors of cytochrome p450 subtypes |
| JP7750582B2 (ja) | 2021-09-14 | 2025-10-07 | 南京邁諾威医薬科技有限公司 | 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途 |
| WO2023240100A1 (en) * | 2022-06-07 | 2023-12-14 | Clarkson Clay Carew | A method to encapsulate non-polar compounds to achieve extended thermal stability and attenuate/prevent thermal and redox isomerization |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2443266A (en) * | 1944-09-02 | 1948-06-15 | Bendix Aviat Corp | Commutator brush holder |
| US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| US5847009A (en) | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
| SE8600632D0 (sv) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| WO1993005786A1 (en) | 1991-09-13 | 1993-04-01 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
| US5411737A (en) | 1991-10-15 | 1995-05-02 | Merck & Co., Inc. | Slow release syneresing polymeric drug delivery device |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| ATE195654T1 (de) | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| JP2002500616A (ja) | 1994-07-21 | 2002-01-08 | ファルマシア・アンド・アップジョン・カンパニー | 神経学的に活性なアミノステロイド |
| DE69519945T2 (de) | 1994-11-23 | 2001-06-07 | Cocensys, Inc. | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| ES2193921T3 (es) | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
| US6442887B2 (en) | 2000-02-25 | 2002-09-03 | Robert L. Sanquist | Live bait keeper |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| EP1360310A2 (en) | 2001-02-13 | 2003-11-12 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| NZ529417A (en) | 2001-05-24 | 2006-11-30 | Alexza Pharmaceuticals Inc | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| US20030032638A1 (en) | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
| JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| AU2003252827B2 (en) | 2002-01-14 | 2008-01-10 | Ansell Healthcare Products Llc | Magnetically detectable latex articles |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| CA2496867A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| WO2005011612A2 (en) | 2003-07-31 | 2005-02-10 | The Research Foundation Of State University Of New York | Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| CA2550432A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ATE497787T1 (de) | 2004-03-12 | 2011-02-15 | Cipla Ltd | Sterilisationsprozess für steroide |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| ITMI20041763A1 (it) | 2004-09-16 | 2004-12-16 | Altergon Sa | Nuove formulazioni iniettabili contenenti progesterone |
| WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| EP1807118B8 (en) | 2004-09-29 | 2014-04-23 | Harbor Therapeutics, Inc. | Steroid analogs and characterization and treatment methods |
| PT2261236E (pt) | 2004-12-07 | 2015-10-30 | Onyx Therapeutics Inc | Composição para a inibição de proteassoma |
| JP2008530134A (ja) | 2005-02-15 | 2008-08-07 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤 |
| PT1868614E (pt) * | 2005-03-24 | 2012-11-23 | Univ Emory | Regime de dosagem para o tratamento de uma lesão cerebral traumática com progesterona |
| US20080207601A1 (en) | 2005-04-07 | 2008-08-28 | Hythiam , Inc. | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| KR100784860B1 (ko) | 2005-10-31 | 2007-12-14 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그 제조 방법 |
| MX2008006888A (es) | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Formulas y metodos para la manufactura y uso de la ganaxolona. |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| RU2486899C2 (ru) | 2007-04-11 | 2013-07-10 | Байомарин Фармасьютикал Инк. | Композиции тетрагидробиоптерина и способы его количественной оценки |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| EP2167098B1 (en) * | 2007-06-11 | 2018-09-05 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| US20100316678A1 (en) | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| WO2009082039A1 (en) | 2007-12-26 | 2009-07-02 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ |
| BRPI0821970A2 (pt) | 2008-01-03 | 2015-06-23 | Biomarin Pharm Inc | Análogos de pterina para tratamento de condição responsiva a bh4 |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| DE102008015366A1 (de) | 2008-03-20 | 2009-09-24 | Merck Patent Gmbh | Lyophilisierte Nanoemulsion |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| CN106243100B (zh) | 2008-10-10 | 2019-04-09 | Vm生物医药公司 | 治疗酒精使用障碍，疼痛和其他疾病的药物组合与方法 |
| CN102300566A (zh) | 2008-11-30 | 2011-12-28 | O·扎查尔 | 血管收缩剂的皮肤应用 |
| WO2010088409A2 (en) * | 2009-01-30 | 2010-08-05 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| WO2010107922A1 (en) | 2009-03-17 | 2010-09-23 | Duke University | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| AU2011207103B2 (en) * | 2010-01-21 | 2013-03-21 | Drawbridge Pharmaceuticals Pty Ltd | Anaesthetic formulation |
| WO2012059456A1 (en) | 2010-11-03 | 2012-05-10 | Sanofi-Aventis Deutschland Gmbh | Needle cannula containing medicament |
| WO2012075286A2 (en) | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| FR2973031B1 (fr) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| AU2012343872B2 (en) | 2011-11-29 | 2016-04-14 | Amino Up Chemical Co., Ltd. | Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent |
| EP2785352B1 (en) | 2011-11-29 | 2020-03-11 | Jurox Pty Ltd | Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone |
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN115381772A (zh) | 2015-02-06 | 2022-11-25 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其用途 |
| GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
| EP3362069A4 (en) | 2015-10-14 | 2019-10-02 | The Regents of The University of California | INCREASING BETA CELL REPLICATION AND / OR SURVIVAL |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| EP3509585B1 (en) | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018169798A1 (en) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
| EP3612186A1 (en) | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
| US11266663B2 (en) | 2017-06-23 | 2022-03-08 | The Board Of Trustees Of The University Of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| EP3642206A4 (en) | 2017-06-23 | 2021-04-07 | The Regents of The University of California | INCREASED GABA ABILITY TO MODULATE IMMUNE REACTIONS |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| EP3681510A1 (en) | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| ES2991092T3 (es) | 2017-12-22 | 2024-12-02 | Sage Therapeutics Inc | Compuestos 19-homo, 3-alfa-hidroxi-esteroides-20-ona para el tratamiento de trastornos del SNC |
| AR114044A1 (es) | 2017-12-22 | 2020-07-15 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central |
| EP3737687B1 (en) | 2018-01-12 | 2025-10-22 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
| CN112823164A (zh) | 2018-05-04 | 2021-05-18 | 阿克罗斯制药公司 | 神经甾体衍生物和其用途 |
| WO2019241442A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US11634453B2 (en) | 2018-10-12 | 2023-04-25 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
| EP3867261B1 (en) | 2018-10-19 | 2025-04-30 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| TWI874337B (zh) | 2018-12-05 | 2025-03-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| JP7692830B2 (ja) | 2018-12-21 | 2025-06-16 | セージ セラピューティクス， インコーポレイテッド | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| CA3163556A1 (en) | 2019-12-05 | 2021-06-10 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| TW202143976A (zh) | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| CA3187178A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2013
- 2013-01-23 NZ NZ773177A patent/NZ773177A/en unknown
- 2013-01-23 DK DK13740743T patent/DK2806877T3/da active
- 2013-01-23 SI SI201331627T patent/SI2806877T1/sl unknown
- 2013-01-23 MX MX2014008895A patent/MX2014008895A/es active IP Right Grant
- 2013-01-23 SG SG11201503882SA patent/SG11201503882SA/en unknown
- 2013-01-23 WO PCT/US2013/022772 patent/WO2013112605A2/en not_active Ceased
- 2013-01-23 AU AU2013212287A patent/AU2013212287B2/en active Active
- 2013-01-23 NZ NZ627781A patent/NZ627781A/en unknown
- 2013-01-23 EP EP19195977.4A patent/EP3650027A1/en not_active Withdrawn
- 2013-01-23 SG SG10201606063RA patent/SG10201606063RA/en unknown
- 2013-01-23 SM SM20200008T patent/SMT202000008T1/it unknown
- 2013-01-23 CN CN202011230446.5A patent/CN112472814A/zh active Pending
- 2013-01-23 JP JP2014553534A patent/JP2015513316A/ja not_active Withdrawn
- 2013-01-23 EP EP13740743.3A patent/EP2806877B2/en active Active
- 2013-01-23 RS RS20191698A patent/RS59734B1/sr unknown
- 2013-01-23 HR HRP20192348TT patent/HRP20192348T1/hr unknown
- 2013-01-23 PT PT137407433T patent/PT2806877T/pt unknown
- 2013-01-23 CN CN201380015855.5A patent/CN104736158A/zh active Pending
- 2013-01-23 ES ES13740743T patent/ES2758446T3/es active Active
- 2013-01-23 RU RU2019104004A patent/RU2019104004A/ru unknown
- 2013-01-23 BR BR112014018110-1A patent/BR112014018110B1/pt active IP Right Grant
- 2013-01-23 RU RU2014134316A patent/RU2681835C2/ru active
- 2013-01-23 CA CA2862076A patent/CA2862076C/en active Active
- 2013-01-23 LT LT13740743T patent/LT2806877T/lt unknown
- 2013-01-23 PL PL13740743T patent/PL2806877T3/pl unknown
- 2013-01-23 EP EP23192903.5A patent/EP4295908A3/en not_active Withdrawn
- 2013-01-23 US US14/374,080 patent/US20150018327A1/en not_active Abandoned
- 2013-01-23 HU HUE13740743A patent/HUE046800T2/hu unknown
- 2013-01-23 IL IL286348A patent/IL286348B2/en unknown
- 2013-01-23 IL IL298436A patent/IL298436B2/en unknown
-
2014
- 2014-07-22 ZA ZA2014/05401A patent/ZA201405401B/en unknown
- 2014-07-22 IL IL233744A patent/IL233744B/en active IP Right Grant
- 2014-07-23 MX MX2019009739A patent/MX2019009739A/es unknown
- 2014-07-23 MX MX2022010976A patent/MX2022010976A/es unknown
-
2017
- 2017-07-13 US US15/649,583 patent/US10322139B2/en active Active
- 2017-12-11 JP JP2017236676A patent/JP2018076341A/ja active Pending
-
2018
- 2018-02-22 AU AU2018201307A patent/AU2018201307B2/en active Active
-
2019
- 2019-04-26 US US16/396,065 patent/US11426417B2/en active Active
- 2019-12-12 CY CY20191101309T patent/CY1122527T1/el unknown
-
2020
- 2020-05-11 JP JP2020082943A patent/JP2020128409A/ja active Pending
- 2020-07-30 IL IL276403A patent/IL276403B/en unknown
- 2020-08-13 AU AU2020217402A patent/AU2020217402B2/en active Active
-
2022
- 2022-04-26 JP JP2022072014A patent/JP7343651B2/ja active Active
- 2022-07-20 US US17/869,145 patent/US20230149424A1/en not_active Abandoned
-
2023
- 2023-08-31 JP JP2023140708A patent/JP2023162368A/ja active Pending
-
2024
- 2024-07-11 US US18/769,514 patent/US20250186459A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ773177A (en) | Neuroactive steroid formulations and methods of treating cns disorders | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2019002669A (es) | Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd). | |
| HK1211525A1 (en) | Laquinimod and pridopidine for treating neurodegenerative disorders | |
| EP2968881A4 (en) | APPARATUS, SYSTEMS AND METHODS FOR BRAIN MEDICATION ADMINISTRATION FOR TREATING NEUROLOGICAL CONDITIONS | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| MX2015014438A (es) | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| PH12015500062A1 (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | |
| MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
| IL235852A0 (en) | A pharmaceutical preparation for the treatment and prevention of psychological, behavioral and cognitive disorders | |
| PT2774991T (pt) | Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos | |
| LT2774991T (lt) | Vaisto įvedimo sistema, skirta naudoti neurologinių sutrikimų gydymui arba diagnostikai | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| PH12014501573A1 (en) | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| Ito | Investigation of a new treatment outcome index for tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 23 JAN 2023 BY SPRUSON + FERGUSON PTY LTD Effective date: 20230118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2024 BY SPRUSON + FERGUSON PTY LTD Effective date: 20230202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2025 BY CPA GLOBAL Effective date: 20231207 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241227 |